

Granules India Awarded India's Most Admired Company in Exports & India's Most Admired Company in Bulk Drugs

September 24, 2012

PRESS RELEASE

Mumbai, September 24, 2012

Granules India Awarded India's Most Admired Company in Exports & India's Most Admired Company in Bulk Drugs

Granules India Ltd., a fast growing pharmaceutical manufacturing Company, announced it has been recognized as India's Most Admired Company in Exports & India's Most Admired Company in Bulk Drugs at the 5th Annual Pharmaceutical Business Leadership Awards organized by Pharmaleaders in association with BSE, Pharmexcil and IBEF.

"We are proud to receive these awards since they recognize our long-term efforts to add value for our customers. Manufacturing efficiency is our top priority and is why we are able to offer an optimal blend of quality and value. We have earned the trust of brand owners and leading generics companies, which is why more than 90% of our business is from exports with 66% coming from North America and Europe. Due to the strong performance of our Finished Dosage Division, we expect our export business to continue to increase" said Mr. Harsha, Executive Director, Granules India Limited after receiving the awards from His Excellency Shri K. Sankaranarayanan, Hon'ble Governor, Government of Maharashtra.

"In order to provide further value to customers, we actively invest in process development R&D, offer value-add products such as rapid-release caplets and provide access to regulated markets through ANDAs and dossiers. We have demonstrated the value proposition India offers by becoming among the premier global companies for our products. In order to drive further value, we have been actively adding capacity across all our manufacturing facilities." added Mr. C. Krishna Prasad, Managing Director, Granules India Limited.

About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 50 countries through offices in India, U.S., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

Granules has the largest PFI facility in the world with an industry leading 6 ton batch size. The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Granules has strengthened its advantages through its Operational Excellence (OE) department which looks at every step of the manufacturing process in order to gain efficiencies and has also implemented systems that have standardized quality and reduced variation. The Company's OE program is regularly cited by MNCs as a "best in class" program and is the comparative advantage that lets Granules provide world-class quality products at a lower cost than its competitors. The adoption of the OE philosophy by Granules has earned it several recognitions including The Economic Times Manufacturing Excellence Award 2011.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.